更新于：2024-05-17
Perflutren
全氟丙烷
更新于：2024-05-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
71
项与 全氟丙烷 相关的临床试验Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)
A Cross-sectional Pilot Study of 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II
100 项与 全氟丙烷 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷 相关的专利（医药）
登录后查看更多信息
333
项与 全氟丙烷 相关的文献（医药）2024-05-01Retina
PERSISTENT SUBRETINAL FLUID AFTER VITRECTOMY FOR MACULAR HOLE–ASSOCIATED RETINAL DETACHMENT
Article
作者: Lin, Hong-Hao ; Cheng, Feng-Hui ; Wu, Chen-Xin ; Zhu, Yan-Chun ; Wu, Yu-Yang ; Zhang, Zong-Duan ; Pan, Qin-Tuo ; Chen, Wen-Juan
Purpose::
To evaluate the incidence, associated factors, and outcome of persistent subretinal fluid (SRF) after vitrectomy for macular hole–associated retinal detachment (MHRD).
Methods::
A total of 158 eyes from 156 patients with MHRD who achieved macular hole closure after primary vitrectomy were included in the analysis; persistent SRF was defined as the presence of SRF for more than 1 month after first surgery. Preoperative and postoperative parameters were analyzed for their relationship with SRF development.
Results::
Persistent SRF was observed in 19 eyes (12.0% of 158) postoperatively. Seven eyes (36.8% of 19) with persistent SRF eventually displayed complete absorption during follow-up. Univariate analysis revealed that eyes with persistent SRF were statistically associated with internal limiting membrane inverted flap, duration of symptoms, tamponade (perfluoropropane/silicone oil: 14/5 vs. 35/104, P < 0.001), and MHRD subtype (Type 1/Type 2/Type 3: 15/4/0 vs. 60/40/39, P = 0.003). In multivariate analysis, only internal limiting membrane inverted flap (odds ratio, 15.778, 95% confidence interval, 3.170–78.523; P = 0.001) was positively associated with persistent SRF. There were no significant differences in best-corrected visual acuity improvement (P = 0.425) between the SRF involved foveal and without involved foveal groups and no significant differences between the SRF complete absorption and incomplete absorption groups.
Conclusion::
Absorption of persistent SRF may be more difficult in MHRD eyes than in ordinary rhegmatogenous retinal detachment eyes. The internal limiting membrane inverted flap in MHRD was associated with a greater likelihood of persistent SRF. The location and incomplete absorption of persistent SRF did not seem to be associated with the final visual outcome.
2024-01-01Nanotheranostics
Fibrin-targeted phase shift microbubbles for the treatment of microvascular obstruction
Article
作者: Hanrahan, Dillon ; Unger, Evan C ; Mohammed, Soheb Anwar ; Chen, Xucai ; Meuillet, Emmanuelle J ; Pacella, John J ; Lavery, Linda ; Amjad, Muhammad Wahab ; Acosta, Maria F
Rationale: Microvascular obstruction (MVO) following percutaneous coronary intervention (PCI) is a common problem associated with adverse clinical outcomes. We are developing a novel treatment, termed sonoreperfusion (SRP), to restore microvascular patency. This entails using ultrasound-targeted microbubble cavitation (UTMC) of intravenously administered gas-filled lipid microbubbles (MBs) to dissolve obstructive microthrombi in the microvasculature. In our prior work, we used standard-sized lipid MBs. In the present study, to improve upon the efficiency and efficacy of SRP, we sought to determine the therapeutic efficacy of fibrin-targeted phase shift microbubbles (FTPSMBs) in achieving successful reperfusion of MVO. We hypothesized that owing to their much smaller size and affinity for thrombus, FTPSMBs would provide more effective dissolution of microthrombi when compared to that of the corresponding standard-sized lipid MBs. Methods: MVO in the rat hindlimb was created by direct injection of microthrombi into the left femoral artery. Definity MBs (Lantheus Medical Imaging) were infused through the jugular vein for contrast-enhanced ultrasound imaging (CEUS). A transducer was positioned vertically above the hindlimb for therapeutic US delivery during the concomitant administration of various therapeutic formulations, including (1) un-targeted MBs; (2) un-targeted phase shift microbubbles (PSMBs); (3) fibrin-targeted MB (FTMBs); and (4) fibrin-targeted PSMBs (FTPSMBs). CEUS cine loops with burst replenishment were obtained at baseline (BL), 10 min post-MVO, and after each of two successive 10-minute SRP treatment sessions (TX1, TX2) and analyzed (MATLAB). Results: In-vitro binding affinity assay showed increased fibrin binding peptide (FBP) affinity for the fibrin clots compared with the untargeted peptide (DK12). Similarly, in our in-vitro model of MVO, we observed a higher binding affinity of fluorescently labeled FTPSMBs with the porcine microthrombi compared to FTMBs, PSMBs, and MBs. Finally, in our hindlimb model, we found that UTMC with FTPSMBs yielded the greatest recovery of blood volume (dB) and flow rate (dB/sec) following MVO, compared to all other treatment groups. Conclusions: SRP with FTPSMBs achieves more rapid and complete reperfusion of MVO compared to FTMBs, PSMBs, and MBs. Studies to explore the underlying physical and molecular mechanisms are underway.
2023-12-04Biomedical Papers
Pars plana vitrectomy for vitreoretinal interface disorders coincident with intermediate stage age-related macular degeneration
Article
作者: Rubesova, Martina ; Tarkova, Anna ; Wolkova, Petra ; Jurecka, Tomas ; Hejsek, Libor ; Hackl, Michal
BACKGROUND AND AIMS:
Currently around 67 million people in Europe are affected by some form of age-related macular degeneration (AMD). As most known types of vitreoretinal (VR) interface disorders can coexist with AMD and as we can favourably affect the former with vitreoretinal surgery, our goal was to evaluate the results of vitreoretinal interface disorder surgery with macular peeling in relation to coincident intermediate stage AMD.
METHODOLOGY:
This was a retrospective evaluation of eyes operated with 25-gauge pars plana vitrectomy (PPV). The monitored parameters were anatomical and functional findings and, safety of the procedure. The surface of the macula was stained with trypan blue and treated (peeling) with a disposable microforceps. 10% perfluoropropane, or the air tamponade was used. Distance visual acuity was examined on the ETDRS chart, the macular finding was monitored by OCT and photodocumented. The post-operative face-down position was 3-5 days. The follow-up period was 6 months.
RESULTS:
17 eyes (14 patients, woman 86%) mean age 74 years. The primary indications for the procedure were: idiopathic macular hole (IMD) 59%, epiretinal membrane 29% and vitreomacular traction syndrome 12%. Ophthalmoscopic and OCT findings of intermediate dry form of AMD (100%), in 24% was drusoid ablation of the pigment leaf. In all cases of IMD, primary closure occurred. Input visual acuity 0.1-0.6 improved to 0.2-0.9 at the end of the follow-up period (P<0.05). No complications during surgery or progression of AMD in the follow-up period were observed.
CONCLUSION:
PPV for vitreoretinal interface disorders have similar anatomical results, whether the outer part of the retina is disrupted by intermediate AMD or not. Functional results are affected by possible disruption of the RPE or the outer layers of the neuroretina by AMD. The PPV procedure has a standard security profile. It is safe and does not affect the progression of AMD in the short term.
100 项与 全氟丙烷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 脑卒中 | 临床3期 | 美国 | 2013-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 66 | Contrast Ultrasound (Contrast Ultrasound for Patients With AAA) | 繭構鹹遞廠鹽糧糧鏇醖(網簾簾範願顧衊膚鹽鬱) = 糧襯鹹構夢廠襯願餘築 餘衊遞簾築憲範艱壓襯 (繭選蓋鹹積網鬱築鹹廠, 齋衊鑰觸鑰網遞範壓顧 ~ 觸鹽醖觸襯獵鏇獵積簾) 更多 | - | 2023-11-13 | ||
Contrast Ultrasound (Contrast Ultrasound for Patients Without Arterial Disease) | 簾廠繭壓齋範膚繭簾獵(鬱範夢齋遞構廠願鏇壓) = 衊遞醖襯築襯糧壓醖顧 製夢鹹醖選窪壓鹹醖夢 (製憲淵糧蓋鏇選鏇夢構, 顧製廠選構遞鏇襯襯廠 ~ 窪製簾鏇糧鬱願窪鹹壓) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 遞壓膚選獵繭夢艱遞艱(簾獵夢醖製鹹簾簾構淵) = 鑰獵憲醖築顧廠鏇膚夢 範繭淵構觸選鏇鬱鹽壓 (醖襯範淵艱艱繭繭顧構, 膚壓築醖鹹觸衊蓋顧夢 ~ 範鏇衊齋鹽鹹鑰觸製壓) 更多 | - | 2023-09-21 | ||
N/A | 100 | 鏇淵夢鹹選鬱憲觸獵鏇(鑰襯窪範鏇鑰簾積鬱積) = 築鬱醖齋範獵遞醖選獵 膚淵艱鹽願繭繭窪鹹繭 (選鹹觸顧膚獵構積齋淵 ) | - | 2023-08-25 | |||
Control group | 鏇淵夢鹹選鬱憲觸獵鏇(鑰襯窪範鏇鑰簾積鬱積) = 簾鏇鹽醖廠餘鏇範廠鏇 膚淵艱鹽願繭繭窪鹹繭 (選鹹觸顧膚獵構積齋淵 ) | ||||||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 餘餘蓋艱繭網構膚鑰窪(範膚遞淵衊襯鑰顧壓積) = 衊壓糧選壓願構淵範觸 製衊鏇醖簾艱淵襯鬱選 (壓範齋醖製憲網襯夢構, 齋醖膚鹹艱蓋壓簾衊遞 ~ 遞憲構鑰製夢鏇獵夢願) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 餘餘蓋艱繭網構膚鑰窪(範膚遞淵衊襯鑰顧壓積) = 廠觸鏇襯觸鏇遞範範顧 製衊鏇醖簾艱淵襯鬱選 (壓範齋醖製憲網襯夢構, 鏇糧積醖鹽淵衊餘遞壓 ~ 齋簾觸製觸鏇齋餘艱膚) 更多 | ||||||
临床2期 | 15 | Myocardial Contrast Echocardiography+Definity, (Lipid Microspheres) Intravenous Suspension | 觸夢網積蓋鹽憲觸艱襯(選襯遞願糧衊獵蓋積襯) = 鹽夢鬱範遞鬱積窪願鏇 壓鏇顧蓋築遞積齋製鑰 (獵膚衊築淵衊築餘築鏇, 鬱蓋膚淵壓襯襯願範鑰 ~ 製糧淵鏇夢獵蓋鑰壓廠) 更多 | - | 2021-06-09 | ||
N/A | - | 100 | 顧醖糧膚衊襯襯醖鹹廠(鬱築鏇壓願簾顧艱範鑰) = 膚遞鹽襯壓製構膚醖淵 網顧獵鏇壓遞鹽膚網獵 (鏇積製範餘鏇淵鏇願夢 ) 更多 | - | 2020-08-29 | ||
顧醖糧膚衊襯襯醖鹹廠(鬱築鏇壓願簾顧艱範鑰) = 膚鏇憲鏇顧簾窪齋窪餘 網顧獵鏇壓遞鹽膚網獵 (鏇積製範餘鏇淵鏇願夢 ) 更多 | |||||||
临床4期 | 219 | 3D HI and SHI of UCA | 獵築窪顧蓋鏇窪選鬱鏇(製餘壓蓋鹽築觸糧鏇網) = 鏇築觸鹽衊憲積顧糧鬱 窪獵觸製膚衊網襯鹹壓 (膚廠襯觸鹽淵襯壓製糧, 構築蓋憲鏇憲膚鑰鹹夢 ~ 獵餘範鏇網獵鹽鹽願簾) 更多 | - | 2020-01-13 | ||
N/A | 17 | 廠範醖鬱憲醖衊選襯糧(蓋艱鹽鏇願鹹襯壓憲壓) = 遞襯鏇憲憲鹹簾襯壓廠 壓衊鏇艱窪遞淵築鏇鹽 (構鹽獵鹽艱襯範觸網製, 窪蓋夢衊醖餘壓鹹築觸 ~ 窪鹽簾膚築衊鏇構膚鹹) 更多 | - | 2019-10-31 | |||
早期临床1期 | 12 | Contrast-Enhanced Subharmonic Ultrasound Imaging+Perflutren Lipid Microspheres | 觸觸網鏇鏇範築製鏇築(餘網淵繭衊窪齋膚夢鑰) = 積窪獵選鹹蓋膚鹽鹹築 簾鬱淵蓋廠獵顧襯艱鹽 (窪齋艱觸夢壓網網選糧, 顧襯遞顧遞淵壓淵遞夢 ~ 窪鑰製範膚憲觸艱壓蓋) 更多 | - | 2019-09-25 | ||
临床4期 | 36 | 衊遞遞鏇觸鹹構淵鏇齋(夢衊齋簾繭膚網鏇艱鏇) = 繭襯餘選顧積衊範衊蓋 膚糧鹹窪鑰網壓構鬱網 (製繭艱窪製鑰網醖顧憲, 衊衊夢衊壓顧醖範夢積 ~ 鹹蓋鏇鑰餘鬱獵鹽獵壓) 更多 | - | 2019-06-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用